Cargando…
Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus
BACKGROUND: Zika virus (ZIKV), a mosquito-borne flavivirus, is a re-emerging virus that constitutes a public health threat due to its recent global spread, recurrent outbreaks, and infections that are associated with neurological abnormalities in developing fetuses and Guillain-Barré syndrome in adu...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990201/ https://www.ncbi.nlm.nih.gov/pubmed/33711018 http://dx.doi.org/10.1371/journal.pntd.0009195 |
_version_ | 1783669032865497088 |
---|---|
author | Vang, Lo Morello, Christopher S. Mendy, Jason Thompson, Danielle Manayani, Darly Guenther, Ben Julander, Justin Sanford, Daniel Jain, Amit Patel, Amish Shabram, Paul Smith, Jonathan Alexander, Jeff |
author_facet | Vang, Lo Morello, Christopher S. Mendy, Jason Thompson, Danielle Manayani, Darly Guenther, Ben Julander, Justin Sanford, Daniel Jain, Amit Patel, Amish Shabram, Paul Smith, Jonathan Alexander, Jeff |
author_sort | Vang, Lo |
collection | PubMed |
description | BACKGROUND: Zika virus (ZIKV), a mosquito-borne flavivirus, is a re-emerging virus that constitutes a public health threat due to its recent global spread, recurrent outbreaks, and infections that are associated with neurological abnormalities in developing fetuses and Guillain-Barré syndrome in adults. To date, there are no approved vaccines against ZIKV infection. Various preclinical and clinical development programs are currently ongoing in an effort to bring forward a vaccine for ZIKV. METHODOLOGY/PRINCIPLE FINDINGS: We have developed a ZIKV vaccine candidate based on Virus-Like-Particles (VLPs) produced in HEK293 mammalian cells using the prM (a precursor to M protein) and envelope (E) structural protein genes from ZIKV. Transient transfection of cells via plasmid and electroporation produced VLPs which were subsequently purified by column chromatography yielding approximately 2mg/L. Initially, immunogenicity and efficacy were evaluated in AG129 mice using a dose titration of VLP with and without Alhydrogel 2% (alum) adjuvant. We found that VLP with and without alum elicited ZIKV-specific serum neutralizing antibodies (nAbs) and that titers correlated with protection. A follow-up immunogenicity and efficacy study in rhesus macaques was performed using VLP formulated with alum. Multiple neutralization assay methods were performed on immune sera including a plaque reduction neutralization test, a microneutralization assay, and a Zika virus Renilla luciferase neutralization assay. All of these assays indicate that following immunization, VLP induces high titer nAbs which correlate with protection against ZIKV challenge. CONCLUSIONS/SIGNIFICANCE: These studies confirm that ZIKV VLPs could be efficiently generated and purified. Upon VLP immunization, in both mice and NHPs, nAb was induced that correlate with protection against ZIKV challenge. These studies support translational efforts in developing a ZIKV VLP vaccine for evaluation in human clinical trials. |
format | Online Article Text |
id | pubmed-7990201 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-79902012021-04-05 Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus Vang, Lo Morello, Christopher S. Mendy, Jason Thompson, Danielle Manayani, Darly Guenther, Ben Julander, Justin Sanford, Daniel Jain, Amit Patel, Amish Shabram, Paul Smith, Jonathan Alexander, Jeff PLoS Negl Trop Dis Research Article BACKGROUND: Zika virus (ZIKV), a mosquito-borne flavivirus, is a re-emerging virus that constitutes a public health threat due to its recent global spread, recurrent outbreaks, and infections that are associated with neurological abnormalities in developing fetuses and Guillain-Barré syndrome in adults. To date, there are no approved vaccines against ZIKV infection. Various preclinical and clinical development programs are currently ongoing in an effort to bring forward a vaccine for ZIKV. METHODOLOGY/PRINCIPLE FINDINGS: We have developed a ZIKV vaccine candidate based on Virus-Like-Particles (VLPs) produced in HEK293 mammalian cells using the prM (a precursor to M protein) and envelope (E) structural protein genes from ZIKV. Transient transfection of cells via plasmid and electroporation produced VLPs which were subsequently purified by column chromatography yielding approximately 2mg/L. Initially, immunogenicity and efficacy were evaluated in AG129 mice using a dose titration of VLP with and without Alhydrogel 2% (alum) adjuvant. We found that VLP with and without alum elicited ZIKV-specific serum neutralizing antibodies (nAbs) and that titers correlated with protection. A follow-up immunogenicity and efficacy study in rhesus macaques was performed using VLP formulated with alum. Multiple neutralization assay methods were performed on immune sera including a plaque reduction neutralization test, a microneutralization assay, and a Zika virus Renilla luciferase neutralization assay. All of these assays indicate that following immunization, VLP induces high titer nAbs which correlate with protection against ZIKV challenge. CONCLUSIONS/SIGNIFICANCE: These studies confirm that ZIKV VLPs could be efficiently generated and purified. Upon VLP immunization, in both mice and NHPs, nAb was induced that correlate with protection against ZIKV challenge. These studies support translational efforts in developing a ZIKV VLP vaccine for evaluation in human clinical trials. Public Library of Science 2021-03-12 /pmc/articles/PMC7990201/ /pubmed/33711018 http://dx.doi.org/10.1371/journal.pntd.0009195 Text en © 2021 Vang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Vang, Lo Morello, Christopher S. Mendy, Jason Thompson, Danielle Manayani, Darly Guenther, Ben Julander, Justin Sanford, Daniel Jain, Amit Patel, Amish Shabram, Paul Smith, Jonathan Alexander, Jeff Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus |
title | Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus |
title_full | Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus |
title_fullStr | Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus |
title_full_unstemmed | Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus |
title_short | Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus |
title_sort | zika virus-like particle vaccine protects ag129 mice and rhesus macaques against zika virus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990201/ https://www.ncbi.nlm.nih.gov/pubmed/33711018 http://dx.doi.org/10.1371/journal.pntd.0009195 |
work_keys_str_mv | AT vanglo zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT morellochristophers zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT mendyjason zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT thompsondanielle zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT manayanidarly zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT guentherben zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT julanderjustin zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT sanforddaniel zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT jainamit zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT patelamish zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT shabrampaul zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT smithjonathan zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus AT alexanderjeff zikaviruslikeparticlevaccineprotectsag129miceandrhesusmacaquesagainstzikavirus |